Health ❯Healthcare ❯Clinical Trials ❯Drug Development
Clinical Trials Precision Medicine Pharmaceuticals Patient Care Oncology Cancer Treatment Medical Research Cancer Research Patient Outcomes
Phase III data validate December’s accelerated FDA decision by confirming the encorafenib, cetuximab and mFOLFOX6 combination as a new standard of care for this aggressive molecularly defined disease.
